Back

Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation: insights from the ARTESiA sub-analysis

31 March 2025 (17:05 - 17:15)
Organised by: Logo
Congress Presentation Part of: Clinical aspects in atrial fibrillation care Oral Anticoagulation EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Deborah Michelle Siegal

University of Ottawa, Ottawa (Canada)

5 More presentations in this session

Presentation thumbnail
Association between atrial fibrillation and dementia, with a particular focus on early-onset dementia: a longitudinal population-based study in catalonia, spain
Mr J. Rodriguez Garcia (Hospitalet De Llobregat, ES)
Abstract Slides Video
Presentation thumbnail
The impact of timing and order of disease development on the risk of mortality in atrial fibrillation and heart failure patients
Ms A. Zandijk (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Randomized comparison of left atrial appendage closure and oral anticoagulation after catheter ablation for atrial fibrillation: subanalysis of AF type
Doctor C. Tondo (Milano, IT)
Abstract Slides Video
Presentation thumbnail
Multimorbidity and risk of atrial fibrillation in the Lifelines Cohort
Miss C. Van Deutekom (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Comparison of CHA2DS2-VA and CHA2DS2-VASc scores for predicting residual risk of stroke and adverse outcomes in anticoagulated patients with atrial fibrillation: a report from a European registry
Doctor D. Mei (Modena, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical aspects in atrial fibrillation care
Video

The Event

Event poster

EHRA 2025

31 March 2025 17:05 CET
You may be interested in
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies
thumbnail
Congress Session
Atrial fibrillation: stroke - oral anticoagulants
thumbnail
Congress Presentation
Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources